BioSpace News Archive

SenesTech, Inc. (NASDAQ: SNES), a developer of proprietary, next generation technologies for managing animal pest populations through fertility control, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of 1,975,000 shares of its common stock at a purchase price of $2.00 per share for gross proceeds of $3.95 million.

Stuart Therapeutics, Inc. (“Stuart”), a clinical stage biopharmaceutical company conducting research and development of unique peptide therapeutics for ophthalmic diseases, today announced the completion of an $11 million Series A round of capital investment.

Capital Health and Temple University Hospital have entered into a affiliation for liver transplant and advanced surgical services that will streamline coordination of care and minimize the amount of travel required by patients in the community served by Capital Health.

Carolina Liquid Chemistries Corp. announces the most recent addition to their Point-of-Care product line. Carolina Liquid Chemistries Corp. now has the Emergency Use Authorized Status™ COVID-19/Flu A&B Combo Test from LifeSign, a Princeton BioMeditech Group Company.

The Government of Canada is protecting the health and safety of Canadians, and reducing the spread of COVID-19 and variants of concern in Canada.

HMP Global, today announced it has entered into a definitive agreement to acquire Kestrel Health Information

PepGen, Inc., a biotechnology company developing transformative therapies for individuals living with neuromuscular and neurologic diseases, today announced that Dr. James McArthur , CEO, will present at Stifel’s 3rd Annual CNS Day virtual conference.

Windtree Therapeutics, Inc. (NasdaqCM: WINT) (“Windtree” or the “Company”), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced the pricing of its previously announced public offering of 9,230,500 shares of our common stock

DotLab, a healthcare technology company at the forefront of research and development to combat women’s health conditions, today announced the initiation of EMPOWER, a multi-center cohort study for endometriosis.

Experts from Northern California-based cancer center to join panels responsible for evidence-based recommendations in NCCN Clinical Practice Guidelines and NCCN Guidelines for Patients, among other resources to improve outcomes for people with cancer.